11.01.2013 Views

Targeted development of biosimilar pharmaceutical products

Targeted development of biosimilar pharmaceutical products

Targeted development of biosimilar pharmaceutical products

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Bioassays addressing multiple MoAs<br />

CDC<br />

complement<br />

dependent<br />

cytotoxicity<br />

C1<br />

Membrane<br />

attack<br />

complex<br />

Target cell<br />

FcγRIIIa<br />

Blocking/ Inhibiting RB<br />

Dimerization / Shedding / Internalization<br />

PCD<br />

Effector cell<br />

(NK cells)<br />

ADCC<br />

24 | Thomas Stangler | EAPB SIG Regulatory Aspects for Bio<strong>pharmaceutical</strong>s | October 4th, 2010 | Business use only<br />

Antibody dependent<br />

cellular cytotoxicity<br />

Programmed cell death (apoptosis )

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!